BlackRock Amends Castle Biosciences Stake to 9.2%
Ticker: CSTL · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1447362
| Field | Detail |
|---|---|
| Company | Castle Biosciences Inc (CSTL) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a big chunk of Castle Biosciences, showing continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Castle Biosciences Inc. As of December 31, 2023, BlackRock beneficially owned 2,427,337 shares of Castle Biosciences' Common Stock, representing 9.2% of the company. This is an amendment (Amendment No. 2) to a previous filing, indicating a change in their holdings. This matters to investors because BlackRock is a major institutional investor, and their significant stake and any changes in it can signal confidence or concern about Castle Biosciences' future performance.
Why It Matters
BlackRock's substantial 9.2% ownership in Castle Biosciences Inc. signals strong institutional confidence, which can positively influence other investors' perceptions and potentially the stock price.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a level of confidence.
Analyst Insight
Investors should note BlackRock's continued significant stake as a sign of institutional confidence, but also monitor future filings for any substantial changes in their position, which could signal a shift in their outlook on Castle Biosciences Inc.
Key Numbers
- 2,427,337 — Shares Owned (BlackRock's beneficial ownership in Castle Biosciences Inc. as of December 31, 2023.)
- 9.2% — Ownership Percentage (The percentage of Castle Biosciences Inc.'s Common Stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Castle Biosciences Inc. (company) — the subject company in which shares are held
- 2,427,337 (dollar_amount) — number of shares beneficially owned by BlackRock
- 9.2% (dollar_amount) — percentage of class owned by BlackRock
- December 31, 2023 (date) — date of the event requiring the filing
- January 25, 2024 (date) — date the SC 13G/A was filed
Forward-Looking Statements
- BlackRock will maintain a significant stake in Castle Biosciences Inc. for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What is the purpose of an SC 13G/A filing?
An SC 13G/A is an amendment to a Schedule 13G, which is filed by institutional investors like BlackRock Inc. to report beneficial ownership of 5% or more of a company's stock, indicating a change in their holdings from a previous filing.
Which company is the subject of this SC 13G/A filing?
The subject company of this filing is CASTLE BIOSCIENCES INC, as stated in the 'Name of Issuer' section of the Schedule 13G.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as identified in the 'Names of reporting persons' section of the filing.
What was BlackRock's beneficial ownership percentage in Castle Biosciences Inc. as of the event date?
As of December 31, 2023, BlackRock Inc. beneficially owned 9.2% of the Common Stock of Castle Biosciences Inc.
What is the CUSIP number for Castle Biosciences Inc. Common Stock?
The CUSIP number for Castle Biosciences Inc. Common Stock is 14843C105, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding CASTLE BIOSCIENCES INC (CSTL).